OpenAI Takes on Google With New AI Model Aimed at Drug Discovery (1)

OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way for more scientific breakthroughs.

The ChatGPT maker said Thursday that the model, GPT-Rosalind, is intended for life sciences research, such as helping glean insights from large volumes of data and turning scientific studies into health-care applications for patients. The model will be available initially as a research preview to some of the company’s business customers, OpenAI said. The initial users include drugmaker Amgen Inc., vaccine maker Moderna Inc. and the Allen Institute, a ...